Poster SESSIONS
52
Poster, 23 June 2014
P-05-023
Efficacy and safety of paliperidone ER in pa-
tients with first episode psychosis: An open-
label, prospective, multi-center study
Young-Chul Chung, Jeonju, Republic of Korea
J.-I. Park, D.-H. Cho, S.-W. Hahn, C. Han, M. H.
Jung, J.-H. Kim, S.-W. Kim, K. Y. Lee
P-05-024
Differential effects of the potential antipsy-
chotic d,l-govadine and its isomers on behav-
ioural flexibility; comparison with D1 and D2
selective compounds
Gemma Dalton, Vancouver, BC, Canada
C. Weidman, S. Floresco, A. Phillips
P-05-025
N-Propynyl analogs of beta-phenylethyli-
denehydrazine increase brain levels of gly-
cine and inhibit its uptake by brain slices
Kamaldeep Dhami, Edmonton, Canada
E. MacKenzie, E. Knaus, C. Velazquez-Martinez,
K. Todd, G. Baker
P-05-026
Disruption of regulated AMPA receptor en-
docytosis enhances latent inhibition of two-
way avoidance
Carine Dias, Vancouver, Canada
D. Ashby, Y. T. Wang, A. G. Phillips
P-05-027
Safety and tolerability of cariprazine in long-
term treatment of schizophrenia: Integrated
summary of safety data
Suresh Durgam, Jersey City, USA
H. A. Nasrallah, A. Cutler, Y. Wang, K. Lu,
K. Nagy, I. Laszlovszky
P-05-028
Effect of antipsychotic drugs on bone density
and cortisol level in schizophrenia
Adel El Sheshai, Alexandria, Egypt
P-05-029
The efficacy and safety of aripiprazole once-
monthly in obese and non-obese patients
with schizophrenia; a post-hoc analysis
Anna Eramo, Chicago, USA
M. De Hert, W. Landsberg, L.-F. Tsai, R. A. Baker
P-05-030 (former P-25-038)
Impact of once- versus twice-daily risper-
idone and olanzapine dosing on clinical
outcomes: Findings from the catie schizo-
phrenia study
Hiroyoshi Takeuchi, Toronto, Canada
G. Fervaha, J. Lee, O. Agid, G. Remington
P-05-031 (former P-43-026)
Insight into illness and uncooperativeness
in chronic schizophrenia
Cynthia Siu, Flemington, USA
O. Agid, M. Waye, C. Brambilla, J. W.-K. Choi,
G. Remington, P. Harvey
P-06
POSTER SESSION
17:15–18:45
Hall B
Neurodegeneration A
P-06-001
ASP5736, a novel, selective and brain-pen-
etrable serotonin 5-HT5A receptor antago-
nist, ameliorates cognitive deficits in rodent
models of Alzheimer‘s disease
Katsuya Harada, Tsukuba-Shi, Ibaraki, Japan
M. Okabe, M. Yamazaki, N. Yamamoto, J. Yari-
mizu, M. Fujii, K. Ni
P-06-002
Aripiprazole for the treatment of psychotic
symptoms in patients with Lewy bodies:
A case series
Yuka Kikuchi, Akita, Japan
M. Sasaki, T. Shimomura, T. Kanbayashi, T. Shi-
mizu
P-06-003
Studies of the mechanism of action in pro-
tective effect against neuronal cell death of
4-phenylbutyrate and its derivatives for ther-
apeutic agents of neurodegenerative disease
Seisuke Mimori, Choshi, Japan
H. Ohtaka, K. Kawada, M. Kaneko, Y. Nomura,
Y. Okuma, Y. Murakami, H. Hamana
P-06-004
Role of vesicular release in l-DOPA-evoked
increases in extracellular dopamine in the
6-OHDA lesioned striatum
Soyon Ahn, Vancouver, Canada
B. Ma, A. Phillips
P-06-005
Effect of the timing of acetylcholinesterase
inhibitor ingestion on sleep
Won-Myong Bahk, Seoul, Republic of Korea
H. R. Song, Y. S. Woo, H. R. Wang, T.-Y. Jun,
M. D. Kim, Y. J. Kwon
P-06-006
Catechin attenuates post stroke neurological
complications by suppressing NF-KB sig-
nalling pathway in collagenase treated rats
Ranjana Bhandari, Chandigarh, India
A. Kuhad
